Related Experiment Video

Updated: Jun 3, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

[Gene and Cell Technologies for Treatment of Brain Malignancies]

I I Abdrakhmanova1,2, K V Kitaeva1, A V Gorodilova1

  • 1Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, 420008 Russia.

Molekuliarnaia Biologiia
|June 2, 2026
PubMed

Insights

Gene and cell therapies offer new hope for treating aggressive brain cancers like glioblastoma. Integrating these advanced treatments may improve patient survival by overcoming treatment resistance and the blood-brain barrier.

Area of Science:

  • Neuro-oncology
  • Cancer Gene Therapy
  • Cellular Therapy

Background:

  • Brain malignancies, including glioblastoma, are highly aggressive and resistant to conventional treatments due to tumor heterogeneity and invasive growth.
  • Recent advancements in gene and cell technologies present novel therapeutic avenues for brain tumors.
  • Overcoming challenges like the blood-brain barrier and the immunosuppressive tumor microenvironment is crucial for effective treatment.

Purpose of the Study:

  • To systematically review current treatment strategies for brain malignancies, focusing on gene and cell therapies.
  • To analyze preclinical and clinical studies evaluating these advanced therapeutic approaches.
  • To explore prospects for overcoming key limitations in treating central nervous system tumors.

Main Methods:

  • Systematic literature review of gene therapy, cell therapy, and combined approaches for brain tumors.
  • Analysis of preclinical and clinical trial data.
  • Evaluation of strategies to address the blood-brain barrier, tumor microenvironment, and toxicity.

Main Results:

  • Gene and cell technologies show promise for targeted therapy, immunotherapy, and personalized medicine in brain cancer.
  • Combined gene and cell therapies offer potential for enhanced efficacy.
  • Progress is being made in overcoming biological barriers and improving treatment safety.

Conclusions:

  • Integration of gene and cell technologies provides a strong foundation for developing effective treatments for central nervous system tumors.
  • These advanced therapies hold the potential to significantly improve survival rates for patients with aggressive brain malignancies.
  • Further research and clinical translation are essential to fully realize the benefits of gene and cell therapies in neuro-oncology.
Keywords:
brain tumorchimeric antigen receptordendritic cellsextracellular vesiclesgene therapyimmunotherapymesenchymal stem cellsoncolytic viruspersonalized medicinetumor microenvironmentviral vectors

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting08:14

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting

Published on: September 25, 2012

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...